Back to search

Article

Persistent<i>IDH</i>mutations are not associated with increased relapse or death in patients with<i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide

2023-08-21

Abstract excerpt

The presence of measurable residual disease (MRD) prior to an allogeneic hematopoietic transplant (alloHCT) in Acute Myeloid Leukemia (AML) has been shown to be associated with an increased risk of post-transplant relapse. Since the Isocitrate Dehydrogenase genes ( IDH1 / 2 ) are mutated in a considerable proportion of patients with AML, we studied if these mutations would serve as useful targets for MRD. Fifty-fi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6adcf743-4804-53a0-87ed-174003426c68
DOI
10.1101/2023.08.14.23294087
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Persistent<i>IDH</i>mutations are not associated with increased relapse or death in patients with<i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamideDOI 10.1101/2023.08.14.23294087
Measurable Residual<i>IDH1</i>before Allogeneic Transplant for Acute Myeloid LeukemiaSemantic proximity
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.Semantic proximity
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.Semantic proximity
Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.Semantic proximity
Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.Semantic proximity
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.Semantic proximity
Pre-MEASURE:<i>FLT3</i>-ITD and mutated<i>NPM1</i>measurable residual disease before allogeneic transplant in adults with AML in first remissionSemantic proximity
Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemiaSemantic proximity
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.Semantic proximity
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.Semantic proximity
IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?Semantic proximity
Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantationSemantic proximity
Select a neighboring publication to make it the new centre.